<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02484651</url>
  </required_header>
  <id_info>
    <org_study_id>2014.145</org_study_id>
    <secondary_id>2014-005238-76</secondary_id>
    <nct_id>NCT02484651</nct_id>
  </id_info>
  <brief_title>Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade?</brief_title>
  <official_title>Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade: a Randomized Controlled Study Assessing Propofol and Remifentanil Requirements and Quality of Recovery in Patients With a Standard Practice of Non-deep Rocuronium Neuromuscular Blockade Versus Deep Neuromuscular Blockade Reversed With Sugammadex</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Hospitalar do Porto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro Hospitalar do Porto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that an anesthetic protocol maintaining deep neuromuscular
      block throughout the entire surgical procedure followed by sugammadex reversal, would
      suppress EMG activity and result in improved anesthetic stability by reducing the variability
      of the Bispectral Index of the EEG, and be beneficial by reducing the total doses of the
      anesthetic drugs propofol and remifentanil required to maintain an adequate level of
      anesthesia (BIS between 40 and 60).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">July 1, 2017</completion_date>
  <primary_completion_date type="Actual">June 28, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BIS signal variability using the measured standard deviation during the maintenance phase of anesthesia</measure>
    <time_frame>Duration of surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Required effect-site concentrations of propofol and remifentanil</measure>
    <time_frame>Duration of surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PQRS results at 15 and 40 minutes after surgery (taking into account the patient baseline values of the PQRS test done on the preanesthetic visit)</measure>
    <time_frame>15 and 40 minutes after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PQRS satisfaction results at day 3 after surgery</measure>
    <time_frame>3rd day after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Neuromuscular Block</condition>
  <arm_group>
    <arm_group_label>Standard Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard Clinical Practice Group - standard neuromuscular block, with a standard rocuronium dose for intubation (0.6 mg/kg). If required, the reversal of neuromuscular block is performed with neostigmine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deep NMB group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deep Neuromuscular Block group - with a standard rocuronium dose for intubation (0.6 mg/kg), followed by a constant infusion of rocuronium (10-15 ug/kg/min) to guarantee a PTC less or equal to 2 on the TOF monitor (PTC is evaluated every 5 minutes). The reversal of neuromuscular block is performed with Sugammadex (4 mg/kg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>Reversal of deep neuromuscular block</description>
    <arm_group_label>Deep NMB group</arm_group_label>
    <other_name>Org 25969</other_name>
    <other_name>Bridion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium</intervention_name>
    <description>Maintenance of deep neuromuscular block</description>
    <arm_group_label>Deep NMB group</arm_group_label>
    <other_name>Zemuron</other_name>
    <other_name>Esmeron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ASA I-III

          -  Between 18 - 80 years old

          -  Scheduled for routine cervical surgery

          -  Minimum duration of surgery is 90 minutes and performed with total intravenous
             anaesthesia (TIVA) with the hypnotic propofol, the analgesic remifentanil and the
             neuromuscular relaxant rocuronium

          -  Patients that are able to and do provide a signed informed consent form

        Exclusion Criteria:

          -  Patients with neuromuscular diseases and severe cardiac and respiratory pathologies

          -  Contra indication for any of the drugs used

          -  Not able to complete the baseline PQRS test.

          -  Indication to perform tracheal intubation using fibroscopy

          -  Patients who are pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Amorim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Hospitalar do Porto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Hospitalar do Porto</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2015</study_first_submitted>
  <study_first_submitted_qc>June 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2015</study_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Hospitalar do Porto</investigator_affiliation>
    <investigator_full_name>Pedro Amorim, MD</investigator_full_name>
    <investigator_title>Pedro Amorim, MD</investigator_title>
  </responsible_party>
  <keyword>deep neuromuscular block</keyword>
  <keyword>sugammadex</keyword>
  <keyword>stability of anesthesia</keyword>
  <keyword>suppression of EMG activity</keyword>
  <keyword>PQRS</keyword>
  <keyword>General Anesthesia</keyword>
  <keyword>Quality of Recovery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

